Advertisement

Hématologie et hémostase

Chapter
  • 779 Downloads

Résumé

Déf.: Insuffisance de l’hématopoïèse (moelle osseuse) avec pancytopénie (bi- ou tricytopénie). Caractéristiques: moelle osseuse hypocellulaire avec substitution graisseuse; pas d’altération des cellules stromales de la moelle osseuse; absence de cellules malignes.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Réf.

  1. 1.
    Bacigalupo A, Bruno B, Saracco P et al. Antilymphocyte globulin, cyclosporin, and granulocyte colony-stimulating factor for severe aplastic anemia: an update of the GITMO/EBMT Working Party. Blood 2000;95:1931–1934PubMedGoogle Scholar
  2. 2.
    Ball SE. The modern management of severe aplastic anaemia. Br J Haematol 2000;110:41–53PubMedGoogle Scholar
  3. 3.
    Brodsky RA, Jones RJ. Aplastic anaemia. Lancet 2005;365:1647–1656PubMedGoogle Scholar
  4. 4.
    Davies JK, Guinan EC. An update on the management of severe idiopathic aplastic anaemia in children. Br J Haematol 2007;136:549–564PubMedGoogle Scholar
  5. 5.
    Geroges GE, Storb R. Stem cell transplantation for aplastic anemia. Int J Hematol 2002;75:141–146Google Scholar
  6. 6.
    Kojima S, Hibi S, Kosaka Y et al. Immunosuppressive therapy using antithymocyte globulin, cyclosporin, and danazol with or without human granulocyte colony-stimulating factor in children with acquired aplastic anemia. Blood 2000;96:2049–2054PubMedGoogle Scholar
  7. 7.
    Marsh JCW, Ball SE, Darbyshire P et al. British Committee for Standards in Hematology (BCSH). Guidelines for the diagnosis and management of acquired aplastic anemia. Br J Haematol 2003;123:782–790PubMedGoogle Scholar
  8. 8.
    Yamaguchi H, Calado RT, Ly H et al. Mutations in TERT, the gene for telomerase reverse transcriptase, in aplastic anemia. N Engl J Med 2005;352:1413–1424PubMedGoogle Scholar
  9. 9.
    Young NS. Immunosuppressive treatment of acquired aplastic anemia and immune-mediated bone marrow failure syndromes. Int J Hematol 2002;75:129–140PubMedGoogle Scholar

Réf.

  1. 1.
    Berliner N, Horwitz M, Loughran TP Jr. Congenital and acquired neutropenia. Hematology (ASH Educ Program) 2004:63–79Google Scholar
  2. 2.
    Boxer LA, Newburger PE. A molecular classification of congenital neutropenia syndromes. Pediatr Blood Cancer 2007;49:609–614PubMedGoogle Scholar
  3. 3.
    Lakshman R, Finn A. Neutrophil disorders and their management. J Clin Pathol 2001;54:7–19PubMedGoogle Scholar
  4. 4.
    Manny N, Zelig O. Laboratory diagnosis of autoimmune cytopenias. Curr Opin Hematol 2000;7:414–419PubMedGoogle Scholar
  5. 5.
    Palmblad JE, von dem Borne AE. Idiopathic, immune, infectious and idiosyncratic neutropenias. Semin Hematol 2002;39:113–120PubMedGoogle Scholar
  6. 6.
    Weite G, Zeidler C, Dale DC. Severe congenital neutropenia. Semin Hematol 2006;43:189–195Google Scholar

Réf.

  1. 1.
    Aster RH, Bougie DW. Drug-induced immune thrombocytopenia. N Engl J Med 2007;357:580–587PubMedGoogle Scholar
  2. 2.
    Bolton-Maggs PHB, Chalmers EA, Collins PW et al. A review of inherited platelet disorders with guidelines for their management on behalf of the UKHCDO. Br J Haematol 2006;135:603–633PubMedGoogle Scholar
  3. 3.
    Cines DB, Bussel JB, McMillan RB et al. Congenital and acquired thrombocytopenia. Hematology (ASH Educ Program) 2004:390–406Google Scholar
  4. 4.
    Deutsch VR, Tomer A. Megakaryocyte development and platelet production: Br J Haematol 2006;134:453–466PubMedGoogle Scholar
  5. 5.
    Drachman JG. Inherited thrombocytopenia: when a low platelet count does not mean ITP. Blood 2004;103:390–398PubMedGoogle Scholar
  6. 6.
    Geddis AE, Kaushansky K. Inherited thrombocytopenias: toward a molecular understanding of disorders of platelet production. Curr Opin Pediatr 2004;16:15–22Google Scholar
  7. 7.
    George JN. Platelets. Lancet 2000;355:1531–1539PubMedGoogle Scholar
  8. 8.
    Jelic S, Radulovic S. Chemotherapy-associated thrombocytopenia. Ann J Cancer 2006;5:371–382Google Scholar

Réf.

  1. 1.
    Andemariam B, Bussel J. New therapies for ITP. Curr Opin Hematol 2007;14:427–431PubMedGoogle Scholar
  2. 2.
    British Committee for Standards in Hematology (BCSH). Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and pregnancy. Br J Haematol 2003;120:574–596Google Scholar
  3. 3.
    Bussel JB, Kuter DJ, George JN et al. AMG 531, a thrombopoiesis stimulating protein, for chronic ITP. N Engl J Med 2006;355:1672–1681PubMedGoogle Scholar
  4. 4.
    Cines DB, McMillan R. Management of adult idiopathic thrombocytopenic purpura. Annu Rev Med 2005;56:425–442PubMedGoogle Scholar
  5. 5.
    George JN, Woolf SH, Raskob GE. Idiopathic thrombocytopenic purpura: a guideline for diagnosis and management of children and adults. American Society of Hematology. Ann Med 1998;30:38–44PubMedGoogle Scholar
  6. 6.
    McMillan R, Durette C. Long-term outcomes in adults with chronic ITP after splenectomy failure. Blood 2004;104:956–960PubMedGoogle Scholar
  7. 7.
    Portielle JEA, Westendorp RGJ, Kluin-Nelemans et al. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood 2001;97:2549–2554Google Scholar
  8. 8.
    Stasi R, Stipa E, Masi M et al. Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura. Am J Med 1995;98:436–442PubMedGoogle Scholar

Réf.

  1. 1.
    Alving BM. How I treat heparin-induced thrombopenia and thrombosis. Blood 2003;101:31–37PubMedGoogle Scholar
  2. 2.
    Arepally GM, Ortel TL. Heparin-induced thrombocytopenia. N Engl J Med 2006;355:809–817PubMedGoogle Scholar
  3. 3.
    Keeling D, Davidson S, Watson H. British Committee for Standards in Haematology. The management of heparin-induced thrombocytopenia. Br J Haematol 2006;133:259–269PubMedGoogle Scholar
  4. 4.
    Newman PM, Chong BH. Heparin-induced thrombocytopenia: new evidence for the dynamic binding of purified anti-PF4-heparin antibodies to platelets and the resultant platelet activation. Blood 2000;96:182–187PubMedGoogle Scholar
  5. 5.
    Rice L, Attisha WK, Drexler A et al. Delayed-onset heparin-induced thrombocytopenia. Ann Intern Med 2002;136:210–215PubMedGoogle Scholar

Réf.

  1. 1.
    Allford SL, Hunt BJ, Rose P et al. British Committee for Standards in Haematology. Guidelines on the diagnosis and management of the thrombotic microangiopathic purpura. Br J Haematol 2003;120:556–573PubMedGoogle Scholar
  2. 2.
    George JN. Thrombotic thrombocytopenic purpura. N Engl J Med 2006;354:1927–1935PubMedGoogle Scholar
  3. 3.
    Ho VT, Cutler C, Carter S et al. Blood and Marrow Transplant Clinical Trials Network Toxicity Committee Consensus Summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005;11:571–575PubMedGoogle Scholar
  4. 4.
    Levy GG, Motto DG, Ginsburg D. ADAMTS13 turns 3. Blood 2005;106:11–17PubMedGoogle Scholar
  5. 5.
    Plaimauer B, Zimmermann K, Volkel D et al. Cloning, expression and functional characterization of the von Willebrand factor-cleaving protease (ADAMTS13). Blood 2002;100:3626–3632PubMedGoogle Scholar
  6. 6.
    Richards A, Goodship JA, Goodship THJ. The genetics and pathogenesis of HUS and TTP. Curr Opin Nephrol Hypertens 2002;11:431–435PubMedGoogle Scholar
  7. 7.
    Sadler JE, Moake JL, Miyata T et al. Recent advances in thrombotic thrombocytopenic purpura. Hemato-logy (ASH Educ Program) 2004:407–423Google Scholar
  8. 8.
    Tarr PI, Gordon CA, Chandler WL. Shiga-toxin-producing Escherichia coli and haemolytic uremic syndrome. Lancet 2005;365:1073–1086PubMedGoogle Scholar

Réf.

  1. 1.
    Birgegard G, Aapro MS, Bokemeyer C et al. Cancer-related anemia: pathogenesis, prevalence and treatment. Oncology 2005;68(suppl 1):3–11PubMedGoogle Scholar
  2. 2.
    Bokemeyer C, Aapro MS, Courdi A et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer 2004;40:2201–2216PubMedGoogle Scholar
  3. 3.
    British Committee for Standards in Hematology (BCSH). Guidelines for the clinical use of red cell transfusion. Br J Haematol 2001;113:24–31Google Scholar
  4. 4.
    Littlewood TJ. The impact of hemoglobin levels on treatment outcomes in patients with cancer. Semin Oncol 2001;28(suppl 8):49–53PubMedGoogle Scholar
  5. 5.
    Provan D, Weatherall D. Red cells I: inherited anaemias. Lancet 2000;355:1169–1175PubMedGoogle Scholar
  6. 6.
    Provan D, Weatherall D. Red cells II: acquired anemias and polycythaemia. Lancet 2000;355:1260–1268PubMedGoogle Scholar
  7. 7.
    Rizzo JD, Somerfleld MP, Hagerty KL et al. ASH/ASCO 2007 clinical practice guideline update on the use of epoetin and darbepoetin. Blood 2007;111:x–yGoogle Scholar

Réf.

  1. 1.
    Donovan A, Andrews NC. The molecular regulation of iron metabolism. Hematol J 2004;5:373–380PubMedGoogle Scholar
  2. 2.
    Goodnough LT, Skikne B, Brugnara C. Erythropoietin, iron, and erythropoiesis. Blood 2000;96:823–833PubMedGoogle Scholar
  3. 3.
    Littlewood TJ. The impact of hemoglobin levels on treatment outcomes in patients with cancer. Semin Oncol 2001;28(2 suppl 8):49–53PubMedGoogle Scholar
  4. 4.
    Means RT. Advances in the anemia of chronic disease. Int J Hematol 1999;70:7–12PubMedGoogle Scholar
  5. 5.
    Thomas C, Thomas L. Anemia of chronic disease: pathophysiology and laboratory diagnosis. Lab Hematol 2005;11:14–23PubMedGoogle Scholar
  6. 6.
    Umbreit J. Iron deficiency. Am J Hematol 2005;78:435–443Google Scholar
  7. 7.
    Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005;352:1011–1023PubMedGoogle Scholar
  8. 8.
    Zimmermann MB, Hurrell RF. Nutritional iron deficiency. Lancet 2007;370:511–520PubMedGoogle Scholar

Réf.

  1. 1.
    Dharmarajan TS, Norkus EP. Approaches to vitamin B12 deficiency. Early treatment may prevent devastating complications. Postgrad Med 2001;110:99–105PubMedGoogle Scholar
  2. 2.
    Fenech M. The role of folic acid and vitamin B12 in genomic stability of human cells. Mutat Res 2001;475:57–67PubMedGoogle Scholar
  3. 3.
    Provan D, Weatherall D. Red cells II: acquired anaemias and polycythaemia. Lancet 2000;355:1260–1268PubMedGoogle Scholar
  4. 4.
    Toh BH, van Driel IR, Gleeson PA. Pernicious anemia. N Engl J Med 1997;337:1441–1448PubMedGoogle Scholar
  5. 5.
    Wickramashinghe SN. The wide spectrum and unresolved issues of megaloblastic anemia. Semin Hematol 1999;36:3–18Google Scholar
  6. 6.
    Zittoun J, Zittoun R. Modern clinical testing strategies in cobalamin and folate deficiency. Semin Hematol 1999;36:35–46PubMedGoogle Scholar

Réf.

  1. 1.
    Borgna-Pignatti C. Moden treatment of thalassaemia intermedia. Br J Haematol 2007;138:291–304PubMedGoogle Scholar
  2. 2.
    British Committee for Standards in Haematology. Guidelines for the diagnosis and management of hereditary spherocytosis. Br J Haematol 2004;126:455–474Google Scholar
  3. 3.
    Gallagher PG. Hereditary elliptocytosis: spectrin and protein 4.1R. Semin Hematol 2004;41:142–164PubMedGoogle Scholar
  4. 4.
    Gertz A. Management of cold haemolytic syndrome. Br J Haematol 2007;138:422–429PubMedGoogle Scholar
  5. 5.
    Hillmen P, Young NS, Schubert J et al. The complement inhibitor eculizumab in PNH. N Engl J Med 2006;355:1233–1243PubMedGoogle Scholar
  6. 6.
    King KE, Ness PM. Treatment of autoimmune hemolytic anemia. Semin Hematol 2005;42:131–136PubMedGoogle Scholar
  7. 7.
    Mehta A, Mason PJ, Vulliamy TJ. Glucose-6-phosphate dehydrogenase deficiency. Baillieres Best Pract Res Clin Haematol 2000;13:21–38PubMedGoogle Scholar
  8. 8.
    Stuart MJ, Nagel RL. Sickle-cell disease. Lancet 2004;364:1343–1360PubMedGoogle Scholar

Réf.

  1. 1.
    Eckardt KU. Pathophysiology of renal anemia. Clin Nephrol 2000;53(1 suppl):S2–8PubMedGoogle Scholar
  2. 2.
    Eschbach JW. Current concepts of anemia management in chronic renal failure: impact of NKF-DOQI. Semin Nephrol 2000;20:320–329PubMedGoogle Scholar
  3. 3.
    MacDougall IC. Novel erythropoiesis stimulating protein. Semin Nephrol 2000;20:375–381PubMedGoogle Scholar
  4. 4.
    Ritz E, Schwenger V. The optimal target hemoglobin. Semin Nephrol 2000;20:382–386PubMedGoogle Scholar
  5. 5.
    Valderrabano F. Quality of life benefits of early anaemia treatment. Nephrol Dial Transplant 2000;15(suppl 3):23–28PubMedGoogle Scholar

Réf.

  1. 1.
    Baglin T, Barrowcliffe TW, Cohen A et al. Guidelines on the use and monitoring of heparin. Br J Haematol 2006;133:19–34PubMedGoogle Scholar
  2. 2.
    Dahlback B. Blood coagulation. Lancet 2000;355:1627–1632PubMedGoogle Scholar
  3. 3.
    Falanga A. Tumor cell prothrombotic properties. Haemostasis 2001;31(suppl 1):1–4Google Scholar
  4. 4.
    Manucci PM, Duga S, Peyvandi R Recessively inherited coagulation disorders. Blood 2004;104:1243–1252Google Scholar
  5. 5.
    Petralia GA, Lemoine NR, Kakkar AK. Mechanisms of disease: the impact of antithrombotic therapy in cancer patients. Nat Clin Pract Oncol 2005;2:356–363PubMedGoogle Scholar

Réf.

  1. 1.
    Dahlback B. Blood coagulation and its regulation by anticoagulant pathways: genetic pathogenesis of bleeding and thrombotic diseases. J Intern Med 2005;257:209–223PubMedGoogle Scholar
  2. 2.
    Delgado J, Jimenez-Yuste V, Hernandez-Navarro%F et al. Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors. Br J Haematol 2003;121:21–35PubMedGoogle Scholar
  3. 3.
    Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med 2002;346:752–763PubMedGoogle Scholar
  4. 4.
    Li T, Chang CY, Jin DY et al. Identification of the gene for vitamin K epoxide reductase. Nature 2004;427:541–544PubMedGoogle Scholar
  5. 5.
    Wiestner A, Cho HJ, Asch AS et al. Rituximab in the treatment of acquired factor VIII inhibitors. Blood 2002;100:3426–3428PubMedGoogle Scholar
  6. 6.
    Zeitler H, Ulrich-Merzenich G, Hess L et al. Treatment of acquired hemophilia by the Bonn-Malmö protocol. Blood 2005;105:2287–2293PubMedGoogle Scholar

Réf.

  1. 1.
    Berntorp E. Immune tolerance induction: recombinant vs. human-derived product. Haemophilia 2001;7:109–13PubMedGoogle Scholar
  2. 2.
    Bolton-Maggs P, Pasi KJ. Haemophilia A and B. Lancet 2003;361:1801–1809PubMedGoogle Scholar
  3. 3.
    Evatt BL, Farrugia A, Shapiro AD et al. Haemophilia 2002: emerging risks of treatment. Haemophilia 2002;8:221–229PubMedGoogle Scholar
  4. 4.
    Graw J, Brackmann HH, Oldenburg J et al. Haemophilia A: from mutation analysis to new therapies. Nat Rev Genet 2005;6:488–501PubMedGoogle Scholar
  5. 5.
    Kubisz P, Stasko J. Recombinant activated factor VII in patients at high risk of bleeding. Hematology 2004;9:317–332PubMedGoogle Scholar
  6. 6.
    Srivastava A. Dose and response in haemophilia: optimization of factor replacement therapy. Br J Haema-tol 2004;127:12–25Google Scholar
  7. 7.
    Van den Berg HM, Fischer K, van der Bom JG. Comparing outcomes of different treatment regimens for severe haemophilia. Haemophilia 2003;9:27–31PubMedGoogle Scholar

Réf.

  1. 1.
    Berntorp E, Astermark J, Björkman S et al. Consensus perspectives on prophylactic therapy for haemophilia: summary statement. Haemophilia 2003;9(suppl 1):l–4Google Scholar
  2. 2.
    Bolton-Maggs P, Pasi KJ. Haemophilia A and B. Lancet 2003;361:1801–1809PubMedGoogle Scholar
  3. 3.
    Di Michèle D. Inhibitor development in haemophilia B. Br J Haematol 2007;138:305–315Google Scholar
  4. 3.
    Kubisz P, Stasko J. Recombinant activated factor VII in patients at high risk of bleeding. Hematology 2004;9:317–332PubMedGoogle Scholar
  5. 4.
    Srivastava A. Dose and response in haemophilia: optimization of factor replacement therapy. Br J Haematol 2004;127:12–25PubMedGoogle Scholar
  6. 5.
    Stobart K, Iorio A, Wu JK. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B. Cochrane Database Syst Rev 2005;CD003429Google Scholar
  7. 6.
    Van den Berg HM, Fischer K, van der Bom JG. Comparing outcomes of different treatment regimens for severe haemophilia. Haemophilia 2003;9:27–31PubMedGoogle Scholar

Réf.

  1. 1.
    Battle J, Noya MS, Giangrande P et al. Advances in the therapy of von Willebrand disease. Haemophilia 2002;8:301–307Google Scholar
  2. 2.
    Ginsburg D. Molecular genetics of von Willebrand disease. Thromb Haemost 1999;82:585–591PubMedGoogle Scholar
  3. 3.
    Manucci PM. Treatment of von Willebrand’s disease. N Engl J Med 2004;351:683–694Google Scholar
  4. 4.
    Rodeghiero F, Castaman G. Treatment of von Willebrand disease. Semin Hematol 2005;42:29–35PubMedGoogle Scholar
  5. 5.
    Ruggeri ZM. Developing basic and clinical research on von Willebrand factor and von Willebrand disease. Thromb Haemost 2000;84:147–149PubMedGoogle Scholar
  6. 6.
    Sadler JE, Mannucci PM, Berntorp E et al. Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost 2000;84:160–174PubMedGoogle Scholar
  7. 7.
    Schneppenheim R, Budde U. Phenotypic and genotypic diagnosis of von Willebrand disease: a 2004 update. Semin Hematol 2005;42:15–28PubMedGoogle Scholar

Réf.

  1. 1.
    Bernard GR, Vincent JH, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699–709PubMedGoogle Scholar
  2. 2.
    De Cicco M. The prothrombotic state in cancer: pathogenetic mechanisms. Crit Rev Hematol Oncol 2004;50:187–196Google Scholar
  3. 3.
    Franchini M, Manzato F. Update on the treatment of disseminated intravascular coagulation. Hematology 2004;9:81–85PubMedGoogle Scholar
  4. 4.
    Levi M. Disseminated intravascular coagulation: what’s new? Crit Care Clin 2005;21:449–467PubMedGoogle Scholar
  5. 5.
    Toh CH, Dennis M. DIC 2002: a review of disseminated intravascular coagulation. Hematology 2003;8:65–71PubMedGoogle Scholar
  6. 6.
    Warren BL, Reid A, Singer P et al. High dose antithrombin III in severe sepsis. JAMA 2001;286:1869–1878PubMedGoogle Scholar
  7. 7.
    Yanada M, Matsushita T, Suzuki M et al. DIC in acute leukemia: clinical and laboratory features at presentation. Eur J Haematol 2006;77:282–287PubMedGoogle Scholar

Réf.

  1. 1.
    Baglin IP, Cousins D, Keeling DM et al. Recommendations from the British Committee for Standards in Haematology and National Patient Safety Agency. Br J Haematol 2006;136:26–29PubMedGoogle Scholar
  2. 2.
    British Committee for Standards in Haematology (BCSH). Guideline. Investigation and management of heritable thrombophilia. Br J Haematol 2001;114:512–528Google Scholar
  3. 3.
    Francis CW. Prophylaxis for thromboembolism in hospitalized medical patients. N Engl Med 2007;356:1438–1444Google Scholar
  4. 4.
    Klerk CPW, Smorenburg SM, Otten HM et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 2005;23:2130–2135PubMedGoogle Scholar
  5. 5.
    Kyrle PA, Eichinger S. Deep vein thrombosis. Lancet 2005;365:1163–1174PubMedGoogle Scholar
  6. 6.
    Lee AYY, Rickles FR, Julian JA et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 2005;23:2123–2129PubMedGoogle Scholar
  7. 7.
    Lopez JA, Kearon C, Lee AY. Deep venous thrombosis. Hematology (ASH Educ Program) 2004;439-456Google Scholar
  8. 8.
    Lyman GH, Khorana AA, Falanga A et al. ASCO Guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007;25:5490–5505PubMedGoogle Scholar

Copyright information

© Springer-Verlag France, Paris 2011

Authors and Affiliations

There are no affiliations available

Personalised recommendations